IGF-1 Is the Rare Marker Where Optimizing Upward Has a Documented Cost

Authors

The Peptide Dispatch Editorial Team

Summarized & reviewed by The Peptide Dispatch Editorial Team · Last reviewed August 5, 2026

TL;DR — Key Takeaways

Most of the markers worth writing about follow the same shape. Low is bad, high is bad, or the risk climbs steadily in one direction and the only question is where the useful threshold sits. You can hold one idea in your head and be roughly right. IGF-1 does not work that way, and that is the entire reason it is worth a careful read. Insulin-like growth factor 1 is the downstream signal of the…

Overview

This dispatch covers IGF-1 Is the Rare Marker Where Optimizing Upward Has a Documented Cost in the metabolic research category, authored by The Peptide Dispatch Editorial Team. Estimated reading time: 9 minutes. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.

Abstract

Most of the markers worth writing about follow the same shape. Low is bad, high is bad, or the risk climbs steadily in one direction and the only question is where the useful threshold sits. You can hold one idea in your head and be roughly right. IGF-1 does not work that way, and that is the entire reason it is worth a careful read. Insulin-like growth factor 1 is the downstream signal of the growth hormone axis. The pituitary releases growth hormone in pulses, mostly at night, which makes growth hormone itself nearly useless to measure from a single morning draw. The liver responds by producing IGF-1, which circulates bound to carrier proteins and stays relatively stable across the day. So IGF-1 became the practical readout of an axis that is otherwise difficult to sample. It is the number clinicians look at when they want to know what growth hormone has actually been doing. It is also the number that gets treated, in a lot of informal discussion, as something to push up. That framing does not survive contact with the cohort data. The shape of the curve The largest analysis comes from UK Biobank. Investigators included 380,997 participants who had a serum IGF-1 measurement and no history of cancer, cardiovascular disease, or diabetes at baseline, then followed them for a median of 8.8 years, recording 10,753 deaths. Results were published in the European Journal of Endocrinology (DOI). Using restricted cubic splines, the relationship between IGF-1 and mortality came out U-shaped. Compared with the fifth decile, the lowest decile carried a 39 percent higher risk of all-cause death (95% CI 29 to 50 percent), a 20 percent higher risk of cancer death, and a 39 percent higher risk of cardiovascular death. The top of the range was not neutral. The highest decile carried a 17 percent higher risk of all-cause death (95% CI 7 to 28 percent) and a 38 percent higher risk of cardiovascular death (95% CI 11 to 71 percent). The associations held through stratified and…

More from the Research Library

• The Line on Your Blood Test That Predicts Mortality, and Why Nobody Reads It — metabolic
• FDA Advisory Panel Backs 6 of 7 Peptides for Compounding — What the July 23–24 Vote Actually Changes — General
• Your Testosterone Result Is a Number About a Protein You Have Never Heard Of — metabolic
• Your Kidney Function Has Two Different Answers, and the Gap Between Them Predicts Mortality — metabolic
• Your Magnesium Test Is Measuring the Wrong 1 Percent — research
• Your Blood Is a Grease Report — And the One Fat Ratio That Predicts How Long You Live Isn't on Your Panel — research

Educational content — not medical advice. Effects described are drawn from cited research in study subjects.